3 Monster Dividend Stocks to Hold for the Next 10 Years
View original at nasdaq.com3 Monster Dividend Stocks to Hold for the Next 10 Years Key Points AbbVie is a Dividend King that has demonstrated its ability to adapt effectively to daunting challenges…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Enterprise Products Partners pays a distribution yield of 5.5% and has increased its distribution for 27 consecutive years
60% confidenceNextEra Energy ranks as the largest utility company by market cap
60% confidenceAbbVie is a member of the Dividend Kings with a 53-year streak of consecutive dividend increases, including time as part of Abbott Labs, and a forward dividend yield topping 3.2%
60% confidenceEnterprise Products Partners generated resilient cash flow throughout major energy sector disruptions including the 2007-2009 financial crisis, the 2015-2017 oil price collapse, and the 2020-2022 COVID-19 pandemic
60% confidenceData centers hosting AI applications require massive amounts of electric power; natural gas is a great fit for fueling power plants serving these data centers, which should translate to higher volumes through Enterprise's pipelines
60% confidenceNextEra Energy is also the world leader in renewable energy and battery storage
60% confidenceNextEra expects the dividend to rise by roughly 10% in 2026, followed by an average annual growth rate of approximately 6% through 2028
60% confidenceStock Advisor's total average return is 986%, a market-crushing outperformance compared to 208% for the S&P 500
60% confidenceVirginia is the home to the world's largest data center market
60% confidenceAbbVie's growth barely skipped a beat after Humira lost patent exclusivity, thanks to investments in R&D and smart acquisitions that added new growth drivers
60% confidenceAbbVie's pipeline includes around 90 programs, of which roughly 60 are in mid- or late-stage clinical trials
60% confidenceIf you aren't willing to own a stock for 10 years, don't even think about owning it for 10 minutes.
60% confidenceNextEra targets compound annual growth in adjusted earnings per share of at least 8% through 2035
60% confidence
Data points we hold from this source
| AbbVie Inc. · mid late stage clinical trials | 60 programs |
| AbbVie Inc. · consecutive dividend increases | 53 years |
| AbbVie Inc. · pipeline total programs | 90 programs |